A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Public ClinicalTrials.gov record NCT02763579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in chemotherapy-naive participants with ES-SCLC. Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the induction phase followed by maintenance with atezolizumab or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.
Study identification
- NCT ID
- NCT02763579
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 503 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Drug
- Carboplatin Drug
- Etoposide Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 7, 2016 (Actual)
- Primary completion
- Apr 24, 2018 (Actual)
- Completion
- Jul 7, 2022 (Actual)
- Last update posted
- Jul 28, 2023
2016 – 2022
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists - Fort Myers (Broadway) | Fort Myers | Florida | 33901 | — |
| Florida Hospital | Orlando | Florida | 32804 | — |
| Florida Cancer Specialists. | St. Petersburg | Florida | 33705 | — |
| Northwest Georgia Oncology Centers PC - Marietta | Marietta | Georgia | 30060 | — |
| Rush University Medical Center | Chicago | Illinois | 60612-3244 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| Cancer Treatment Centers of America - Midwestern Regional Medical Center | Zion | Illinois | 60099 | — |
| Louisville Oncology | Louisville | Kentucky | 40202 | — |
| New England Cancer Specialists | Scarborough | Maine | 04074 | — |
| Weinberg CA Inst Franklin Sq | Baltimore | Maryland | 21237 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Comprehensive Cancer Centers of Nevada - Eastern Avenue | Las Vegas | Nevada | 89169 | — |
| The Valley Hospital | Paramus | New Jersey | 07652 | — |
| Broome Oncology - Binghamton | Binghamton | New York | 13905 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology PLLC - Nashville (20th Ave) | Nashville | Tennessee | 37203 | — |
| Vanderbilt Medical Center | Nashville | Tennessee | 37232-7610 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
| University of Wisconsin | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 92 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02763579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 28, 2023 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02763579 live on ClinicalTrials.gov.